期刊
CANCER LETTERS
卷 314, 期 1, 页码 8-23出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.09.040
关键词
TRAIL; p53; Apoptosis; Sensitization; Cancer
类别
资金
- Biomedical Research Council (BMRC) of Singapore [R-143-000-349-305]
- Singapore National Medical Research (NMRC)
- BMRC
- Centre for Environmental and Occupational Health, Dept. of EPH, National University of Singapore
- Toxicology Program
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been intensively studied as a cancer therapeutic agent due to its unique ability to induce apoptosis in malignant cells but not in normal cells. However, as more human cancer cells are reported to be resistant to TRAIL treatment, it is important to develop new therapeutic strategies to overcome this resistance. p53 is an important tumor suppressor that is widely involved in cellular responses to various stresses. In this mini-review, we aim to provide an overview of the intricate relationship between p53 and the TRAIL-mediated apoptosis pathway, and to summarize the current approaches of targeting p53 as a therapeutic strategy to sensitize TRAIL-induced apoptosis in human cancer cells. Although in some cases TRAIL kills cancer cells in a p53-independent manner, it is believed that in cancers with wild-type and functional p53, targeting p53 may be an important strategy for overcoming TRAIL-resistance in cancer therapy. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据